Previous 10 | Next 10 |
home / stock / invvy / invvy news
2023-04-29 07:56:06 ET Indivior PLC (INVVY) Q1 2023 Earnings Conference Call April 27, 2023 08:00 AM ET Company Participants Jason Thompson - Vice President of Investor Relations Mark Crossley - Chief Executive Officer Christian Heidbreder - Chief Scientific Offi...
2023-04-28 02:06:35 ET The following slide deck was published by Indivior PLC in conjunction with their 2023 Q1 earnings call. For further details see: Indivior PLC 2023 Q1 - Results - Earnings Call Presentation
Indivior Announces Q1 2023 Financial Results PR Newswire SLOUGH, U.K. , and Richmond, Va. , April 27, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) today announced its financial results for the period ending March 31, 2023 . The earnings release, inv...
Indivior To Participate In Bank of America Global Healthcare Conference 2023 PR Newswire SLOUGH, UK and RICHMOND, Va. , April 25, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) today announced that it will participate in the following investor event: ...
2023-04-07 08:09:06 ET Summary Opioid treatment provider Indivior has seen a 20%+ price rise in 2023, but its latest financials are not supportive. The company swung into a loss for FY22 on the provision for litigation, which is a red flag, considering that these costs could mount...
Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc. PR Newswire Combination Strengthens Indivior's Addiction Treatment and Science Portfolio RICHMOND, Va. , March 2, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) ("Indivior" or the "Company") to...
The following slide deck was published by Indivior PLC in conjunction with their 2023 Q4 earnings call. For further details see: Indivior PLC 2023 Q4 - Results - Earnings Call Presentation
Indivior PLC (INVVY) Q4 2022 Earnings Conference Call February 16, 2023 08:00 ET Company Participants Jason Thompson - Vice President of Investor Relations Mark Crossley - Chief Executive Officer Christian Heidbreder - Chief Scientific Officer Ryan Preblick - Chief...
Indivior PLC ADR press release ( OTCPK:INVVY ): Q4 Non-GAAP EPS of $0.27. Revenue of $241M (+8.6% Y/Y). Guidance: TotalFY2023expectedNRrangeof$950Mto$1,020M(+9%vs.FY2022atthemid-point),reflectingcontinued strongSUBLOCADEandPERSERISgrowthandacceleratedshareerosionforUSSUBOXONEF...
FY 2022 Financial Results Announced PR Newswire SLOUGH, England and RICHMOND, Va. , Feb. 16, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) today announced 2022 Full Year Results. The earnings release, investor presentation, and webcast are available at ww...
News, Short Squeeze, Breakout and More Instantly...
Indivior PLC ADR Company Name:
INVVY Stock Symbol:
OTCMKTS Market:
Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance PR Newswire RICHMOND, Va. , May 23, 2024 /PRNewswire/ -- Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, announced that in anticipation o...
Indivior Announces Q1 2024 Financial Results PR Newswire SLOUGH, United Kingdom and RICHMOND, Va. , April 25, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024 . The earnings re...
Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone PR Newswire This head-to-head pharmacodynamic study in healthy volunteers...